In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access to cutting-edge medicines, with a particular focus on rare diseases, and ensure global pharmaceutical and biotech organisations continue to prioritise the UK as a launch destination.
Join us on Wednesday 23rd November at 12:30 GMT / 13:30 CET / 7:30 am EST as the panel discuss how the Innovative Medicines Fund works, what the implications are for industry organisations in securing funding via this route, and how this will influence uptake of medicines recommended via a NICE technology appraisal.
Angela McFarlane, VP Strategic Planning, IQVIA UK & Ireland and North Europe
As VP, Strategic Planning for IQVIA, Angela works closely with UK Government, the NHS, the Pharmaceutical and Biotech Industry and Patient Organisations on pioneering collaborations that will improve NHS patient access to clinical trials, RWE studies and innovative medicines.
Angela is working to ensure the UK life sciences sector expands its footprint as a priority country for inward investment in research and medicines launch as healthcare ecosystems recover from the impact of COVID-19. She founded the Clinical Research Coalition chaired by Baroness Blackwood to embed the learning from the pandemic, the output of which became Lord Bethell’s Clinical Trial Transformation programme.
In 2018, she was nominated by Pharmaceutical Marketing Europe as one of the 30 most influential women in UK Healthcare, and in September 2019 appointed by the UK’s Chief Scientific Officer to be an Ambassador for Women in Science and Engineering (WISE).
Angela spent a decade in pharma sales and marketing management roles with MSD and BMS, prior to staring the world’s second market access agency in 1998, which she sold to IMS Health in 2013. She is an SME in market access, rare disease and biosimilars.
Nina Pinwill BSc (Hons) MSc DIC, is the Head of Commercial Operations at NHS England and NHS Improvement
Nina Pinwill leads the commercial operations function within the Commercial Medicines Directorate at NHS England. Nina’s role is to ensure that patients have faster access to the most promising new treatments, taxpayers get better value for money in drug expenditure and the route to funding is speeded up for responsibly priced, promising drugs. This includes responsibility for the Innovative Medicines Fund, the Cancer Drugs Fund, industry relations, patient access schemes (PAS), the Blueteq prior approval system, dose banding and budget impact tests. Nina is London based.
Nina received her first degree in Geography in 1995 and spent the next five years in various management and planning roles in the Lord Chancellors Department (now the Ministry of Justice). Nina then spent the next 16 years working at the National Institute for Health and Care Excellence (NICE); the independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health in England. Nina has developed and improved various processes at NICE such as the process for technology appraisal and redesigning how NICE choose the topics it produces guidance on. Following a year’s secondment in 2015 to the Office for Life Sciences (a joint venture between Department of Health and Social Care and Department for Business, Energy & Industrial Strategy) as a Senior Policy Lead working on the Accelerated Access Review, Nina returned to NCIE to set up, launch and subsequently head up the new engagement function for the life sciences sector, called the Office for Market Access.
Nina gained her MSc in Health Policy from Imperial College London in May 2016 and is a trustee for the Waldenström’s Macroglobulinemia UK charity.
Nina’s areas of interest are in strategic planning and developments, managed access approaches, leadership, innovative problem solving, effective programme oversight and delivery.
Sean Richardson, VP & General Manager UK & Ireland, Alexion
Sean Richardson. General Manager Alexion UK, working in the biopharmaceutical industry for 20 years after attaining a BSc in Biochemistry. His focus for the past 5 years has been on rare diseases in the UK, working in collaboration with the rare disease community to improve the patient experience of care, from diagnosis to accessing treatment and co-ordination of care.
Dr Paul Tunnah, chief content officer and managing director UK, Healthware (moderator). Alongside his work as a recognised author, speaker, moderator and industry advisor, he founded the industry-leading publication pharmaphorum in 2009. Dr Tunnah also holds a BA in Biochemistry and DPhil in Biological Sciences from Oxford University, where his work focused on identification of novel anticancer therapies.
This post was originally published on Source Link